silver fluoride

Small moleculeexperimental

Silver Dihydrogen Citrate is a patented antimicrobial based on stabilized silver ion complex produced by a unique electrochemical process with silver and citric acid. Silver Dihydrogen Citrate provides a broad spectrum antimicrobial activity and is effective against unwanted bacteria, fungi, and viruses including pathogenic microorganisms. Its fast killing activity makes Silver Dihydrogen Citrate an effective antimicrobial for many applications. Silver has been used for centuries for its antimicrobial properties. In order for silver to be effective in killing microorganisms, it must be in an ionic form. Silver Dihydrogen Citrate is a complex of one silver ion weakly bound to one citrate ion having the molecular complex AgC6H7O7. Silver Dihydrogen Citrate provides a stabilized form of silver ion in an organic acid (citric acid). The bioavailability of the ions allows for Silver Dihydrogen Citrate to be rapidly effective against a broad spectrum of bacteria, viruses, and fungi. Silver ions are highly attracted to sulfur-containing thiol groups found in metabolic and structural proteins bound to the membrane surface. Silver Dihydrogen Citrate targets these critical proteins and destroys their structure. This disruption of the organisms’ membrane function and integrity lyses the membrane and the organism dies. — NCATS

Clinical trial activity

8 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
4
Phase 4
1

Earliest trial started Sep 1, 2017 (NCT03186261)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Other

Chemistry & pharmacology

Loading structure…

SMILES

[Ag+]
Mol. weight
107.8682 g/mol

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ag-f
  • silver fluoride
  • silver fluoride
  • silver fluoride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06489093Early Phase 1 (Phase 1)Jul 29, 2024Plovdiv Medical University
NCT06348849Phase 2/Phase 3 (Phase 3)Apr 1, 2024Alexandria University
NCT05221749Phase 3Mar 15, 2022Alexandria University
NCT04930458N/AAug 10, 2021University of Baghdad
NCT04887389Phase 4Jul 1, 2021Mansoura University
NCT04929509N/ADec 5, 2020Alexandria University
NCT04804423Phase 2/Phase 3 (Phase 3)Jan 13, 2020SDI Limited, University of Greifswald
NCT03186261Phase 3Sep 1, 2017Cairo University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alexandria UniversityAcademic/Hospital3322020
Cairo UniversityAcademic/Hospital1112017
Mansoura UniversityAcademic/Hospital1112021
Plovdiv Medical UniversityAcademic/Hospital1112024
SDI LimitedFor profit1012020
University of BaghdadAcademic/Hospital1112021
University of GreifswaldAcademic/Hospital1112020
7 organizations
Page 1 / 1